Biolegend, 100229, Brilliant Violet 650™ anti-mouse CD3 Antibody, 125microl

CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex
125microl
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: γδTCR-positive T-T hybridoma D1
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 650™ under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 650™ excites at 405 nm and emits at 645 nm. The bandpass filter 660/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 650™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Additional reported application (for relevant formats) include: spatial biology (IBEX)1,2.
Application References(PubMed link indicates BioLegend citation): Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Komuczki J, et al. 2019. Immunity. 50:1289. PubMed Whyte CE, et al. 2022. Curr Protoc. 2:e589. PubMed Dijkman K, et al. 2023. NPJ Vaccines. 8:66. PubMed Bhaskar A, et al. 2023. iScience. 26:106644. PubMed Oh J, et al. 2023. Nat Commun. 14:3278. PubMed Yamin R, et al. 2021. Nature. 599:465. PubMed Mirchandani AS, et al. 2022. Nat Immunol. 23:927. PubMed Edwards SC, et al. 2023. J Exp Med. 220: . PubMed Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed Trittel S, et al. 2019. Sci Rep. 9:16362. PubMed Larsen SE, et al. 2021. Sci Rep. 11:9040. PubMed Clemmensen HS, et al. 2021. MBio. 12:. PubMed Yoshihara E, et al. 2020. Nature. 606:586. PubMed Bhattacherjee A, et al. 2019. Commun Biol. 2:450. PubMed Cao W, et al. 2017. Immunity. 47:1182. PubMed Woodworth JS, et al. 2021. Nat Commun. 12:6658. PubMed Clemmensen HS, et al. 2020. Front Immunol. 11:585359. PubMed Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed Sophie Thiemann et al. 2017. Cell host & microbe. 21(6):682-694 . PubMed Lissner MM, et al. 2020. Elife. 9:00. PubMed André P et al. 2018. Cell. 175(7):1731-1743 . PubMed Xu J et al. 2018. Cell. 173(3):762-775 . PubMed Mamedov MR, et al. 2018. Immunity. 48:350. PubMed Campbell C et al. 2018. Immunity. 48(6):1245-1257 . PubMed Grauel AL, et al. 2020. Nat Commun. 4.84375. PubMed Sanmarco LM, et al. 2021. Nature. 590:473. PubMed Moguche AO et al. 2017. Cell host & microbe. 21(6):695-706 . PubMed Pasciuto E, et al. 2020. Cell. 182:625. PubMed Cillo AR, et al. 2021. Cell Rep Med. 2:100476. PubMed Contreras NA, et al. 2019. PLoS Pathog. 15:e1007890. PubMed Georgiadou A, et al. 2022. Elife. 11:. PubMed Filskov J, et al. 2019. Sci Rep. 9:14085. PubMed Dhayade S, et al. 2020. Nutrients. 12:. PubMed Demaria O, et al. 2022. Cell Rep Med. 3:100783. PubMed Pattabiraman G, et al. 2021. Am J Physiol Renal Physiol. . PubMed McGinley AM, et al. 2020. Immunity. 52(2):342-356. PubMed Jacobs L, et al. 2022. Cancer Gene Ther. 29:984. PubMed
RRID: AB_11204249 (BioLegend Cat. No. 100229)
Structure: Ig superfamily, CD3/TCR, 20 kD
Distribution: Thymocytes (differentiation dependent), mature T cells, NK-T cells
Function: Antigen recognition, TCR signal transduction, T cell activation
Ligand/Receptor: Peptide antigen/MHC-complex
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Davis MM. 1990. Annu. Rev. Biochem. 59:475. 3. Weiss A, et al. 1994. Cell 76:263.
Gene ID: 12502
UniProt: View information about CD3 on UniProt.org
Clone: 17A2
Regulatory Status: RUO
Other Names: T cell antigen receptor complex, T3
Isotype: Rat IgG2b, κ